Sign in / Join Now
ETFs & Funds
data likely to b > Abraxane
. Abrax trial began 3/09. Near end of trial on 9/11, protocol changed and added 210 pts
Likely had to add pts because initial
data on 630 pts was not good. If
#s good, absolutely no reason to add pts to trial
Th-302 targets hypoxic niche, which should also kill CSCs.
OT- That was a bummer yesterday that Bapi got cancelled. I really thought the Apo4 non-carriers would have some positive news.
Add a reply...
Latest StockTalks »
people get THLD breaking news and analysis by email alert.
Get email alerts on THLD »
Threshold Pharmaceuticals, Inc.
Get latest price
From other sites
Threshold Pharmaceuticals Announces Presentation And Webcast At The Stifel Healthcare Conference 2016
at TheStreet (Nov 15, 2016)
Threshold Pharmaceuticals Reports Third Quarter Financial Results
at TheStreet (Nov 7, 2016)
Caris Life Sciences And Threshold Pharmaceuticals Collaborate To Utilize Caris' ADAPT Biotargeting System In The Development Program For Evofosfamide
at TheStreet (Oct 25, 2016)
Is Threshold Pharmaceuticals a Buy? (THLD)
at Investopedia (Oct 3, 2016)
Mid-Day Market Update: Dow Surges Over 150 Points; Threshold Pharmaceuticals Shares Slide
at Benzinga (Sep 30, 2016)